Forecast

The analysts' average price target is €1,169.75 (+17.98%). The median is €1,199.09 (+20.94%).

Buy	33
Hold	9
Sell	3

News Go to news feed

Eli Lilly's Foundayo captures over 30% of new US oral weight-loss patients

Foundayo, launched in the US in April 2026, has secured more than 30% of new patients starting oral weight-loss medicines, rapidly challenging Novo Nordisk's Wegovy pill. Lilly prices Foundayo from $149/month for self-pay patients and as low as $25 for some commercially insured patients, with a $50/month Medicare Bridge option. The company has submitted Foundayo for a type 2 diabetes indication, which could expand the market, but sustained revenue depends on adherence, pricing pressure from competitors, and potential competition from next-generation therapies like retatrutide. » More on finance.yahoo.com
Eli Lilly posts 48% revenue surge and raises FY2026 guide, cementing growth lead over Merck

Eli Lilly reported Q2 revenue of $22.97 billion, up 47.7% year‑over‑year, driven by Mounjaro ($9.94 billion) and Zepbound ($4.93 billion), and raised its full‑year 2026 revenue guidance to $85–$87 billion with an ~85.8% gross margin. Pipeline catalysts include retatrutide Phase 3 results near bariatric levels and rapid uptake of oral GLP‑1 Foundeo, whose prescriber count jumped from ~8,000 to 36,000 in one quarter. The company is expanding capacity to meet demand, positioning it as a cleaner growth story through 2030 versus Merck, which showed only 5% Q2 growth as KEYTRUDA approaches peak penetration. » More on finance.yahoo.com
Eli Lilly rises after Berenberg upgrade and strong Foundayo numbers

Eli Lilly shares gained in premarket trading after Berenberg raised its rating from "Hold" to "Buy" and lifted the price target from $1,220 to $1,400. The bank cited market leadership with Zepbound and Mounjaro and the expected approval boost from the oral GLP‑1 drug Foundayo. Lilly said Foundayo has captured over 30% of new patients in the U.S. oral obesity market since launch and that the "Medicare Bridge" program now has around 600,000 participants. Analyst consensus remains "Buy" with an average price target just under $1,300, and IQVIA data give Lilly a 60.9% market share versus 38.8% for Novo Nordisk. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2026, Eli Lilly & Co has already paid €4.48 in dividends. The last payout was in September.

Financials

In the last quarter, Eli Lilly & Co had revenue of €20.13B and net profit of €6.22B

(EUR)	June 2026	YoY
Revenue	20.13B	52.50%
Gross profit	17.27B	55.24%
Net profit	6.22B	29.44%
EBITDA	11.38B	78.91%

Fundamentals

Metric	Value
Market capitalization	€933.08B
Number of shares	941.74M
52-week high/low	€1,126.45 - €620.50
Dividend yield	0.58%
Dividends TTM	€5.76
Beta	0.50
P/E ratio	38.04
PEG ratio	0.40
P/B ratio	29.95
P/S ratio	13.44

Company profile

Eli Lilly and Company erforscht, entwickelt und vermarktet weltweit Humanarzneimittel. Es bietet Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, Insulin Lispro, Insulin Lispro Protamin, Insulin Lispro Mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R und Humulin U-500 für Diabetes; und Jardiance, Trajenta und Trulicity für Typ-2-Diabetes. Das Unternehmen bietet Alimta für nicht-kleinzelligen Lungenkrebs (NSCLC) und bösartiges Pleuramesotheliom; Cyramza für metastasierenden Magenkrebs, Adenokarzinom des gastroösophagealen Übergangs, metastasierenden NSCLC, metastasierenden kolorektalen Krebs und hepatozelluläres Karzinom; Erbitux für kolorektale Karzinome und verschiedene Kopf- und Halskrebsarten; Retevmo für metastasierten NSCLC, medullären Schilddrüsenkrebs und Schilddrüsenkrebs; Tyvyt für rezidivierte oder refraktäre klassische Hodgkin-Lymphome und nicht-squamösen NSCLC; und Verzenio für HR+, HER2- metastasierten Brustkrebs, knotenpositiven und frühen Brustkrebs. Es bietet Olumiant für rheumatoide Arthritis und Taltz für Plaque-Psoriasis, psoriatische Arthritis, ankylosierende Spondylitis und nicht-radiographische axiale Spondylarthritis. Das Unternehmen bietet Cymbalta für depressive Störungen, diabetische periphere neuropathische Schmerzen, generalisierte Angststörungen, Fibromyalgie und chronische Muskel-Skelett-Schmerzen; Emgality für Migräne-Prävention und episodische Cluster-Kopfschmerzen; und Zyprexa für Schizophrenie, bipolare Störung und bipolare Erhaltung. Seine Bamlanivimab und Etesevimab und Bebtelovimab für COVID-19; Cialis für erektile Dysfunktion und benigne Prostatahyperplasie; und Forteo für Osteoporose. Das Unternehmen arbeitet mit der Incyte Corporation, Boehringer Ingelheim Pharmaceuticals, Inc., AbCellera Biologics Inc., Junshi Biosciences, Regor Therapeutics Group, Lycia Therapeutics, Inc., Kumquat Biosciences Inc., Entos Pharmaceuticals Inc. und Foghorn Therapeutics Inc. zusammen. Eli Lilly and Company wurde 1876 gegründet und hat seinen Hauptsitz in Indianapolis, Indiana.

Name	Eli Lilly & Co
CEO	David A. Ricks
Headquarters	Indianapolis, in USA
Website	lilly.com
Sector	Health Care
Industry	Pharmaceuticals
IPO	06/01/1972
Employees	50,000